Abstract | BACKGROUND:
Statins are lipid-lowering drugs that exhibit anti-inflammatory and immune-modulatory properties, leading to a reduction of serum levels of C-reactive protein (CRP) in the general population. OBJECTIVE: Because very limited data are available today, our objective was to assess the lipid-lowering effects of statins and their capacity to decrease selected soluble markers of inflammation in HIV-infected patients. METHODS: RESULTS: CONCLUSION:
|
Authors | Leonardo Calza, Filippo Trapani, Michele Bartoletti, Roberto Manfredi, Vincenzo Colangeli, Marco Borderi, Gabriele Grossi, Roberto Motta, Pierluigi Viale |
Journal | HIV clinical trials
(HIV Clin Trials)
2012 May-Jun
Vol. 13
Issue 3
Pg. 153-61
ISSN: 1528-4336 [Print] England |
PMID | 22592095
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents
- Cholesterol, HDL
- Cholesterol, LDL
- HIV Protease Inhibitors
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Tumor Necrosis Factor-alpha
- C-Reactive Protein
- Ritonavir
|
Topics |
- Acquired Immunodeficiency Syndrome
(blood, drug therapy)
- Adult
- Anti-Inflammatory Agents
(pharmacology)
- C-Reactive Protein
(analysis)
- Cholesterol, HDL
(blood)
- Cholesterol, LDL
(blood)
- Cohort Studies
- Female
- HIV Protease Inhibitors
(therapeutic use)
- HIV-1
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(adverse effects, pharmacology)
- Male
- Middle Aged
- Retrospective Studies
- Ritonavir
(therapeutic use)
- Tumor Necrosis Factor-alpha
(blood)
|